CClinicalTrials.gg
CompletedNCT03962907DECO-SSIUpdated Jul 17, 2020

Preoperative Decolonization and Surgical Site Infections in Orthopaedic Surgery - 2 Year Outcome in Prosthetic Surgery

A Phase 4 interventional study of Chlorhexidine, Lifo-Scrub sol 4%®, 500ml, B. Braun and BACTROBAN® Nasal ong in Staphylococcus Aureus, Orthopaedic Surgery and Surgical Site Infection, sponsored by Lindenhofgruppe AG. Completed at 1 site in Switzerland. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2020-07-17.

Sponsored by Lindenhofgruppe AG · Phase 4, Interventional, and Prevention

Phase
Phase 4
Study type
Interventional
Enrollment
1,318
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Study summary

Surgical site infections in orthopaedic surgery are a major problem. Decolonization has been suggested to reduce infection rates. The study was designed as a prospective, controlled, randomized, single-blinded trial to assess the influence of a decolonization procedure in S. aureus and non - S. aureus carriers. In this trial the 2 - year outcome in the subpopulation of prosthetic elective orthopaedic surgery will be evaluated.

Read the detailed description

To verify the main hypothesis, a prospective controlled randomized interventional trial with 2 parallel groups of patients of the Sonnenhof hospital undergoing an elective knee- or hip implant surgery was designed. A superiority framework for the decolonization procedure was used. All patients planned for such a procedure will be recruited during preoperative consultation by the orthopedic surgeons or by post and phone. Written informed consent will be obtained at this occasion. Study participants were screened 2-4 weeks prior intervention for nasal S. aureus colonization.

Study participants were allocated on a 1:1 basis either to an intervention or to a control group, but prosthesis implantation was not defined as randomization criteria in the initial trial. Randomization was stratified for important risk factors of SSI; procedure type (upper extremities and pelvic/hip, spine, knee and foot) and ASA-criteria (I, II, III -V). Stratification-groups were chosen in function of SSI's rate and expected number of operations/year. Randomization list were generated by the CTU and allocation was concealed using central randomization that was implemented in the REDCap data entry system.

One week prior to hospitalization patients in the intervention group received a decolonization kit by mail with instructions to apply mupirocin ointment 2% (BACTROBAN Nasal ong 3g, GSK) in each nostril 30mg (which corresponds approximately the same amount as the volume of a pea) twice a day and to shower daily (starting with the face, then from top to bottom the whole body emphasizing especially on nose, axillaries and pelvic region and then rinse. In a second time starting with the hair and then repeat the whole body. Dry with a proper towel (one for the 5 days)) with 25ml chlorhexidine gluconate soap, (Lifo-Scrub sol 4 % 500ml, B. Braun) during 5 days prior surgery. For non S. aureus carriers only skin cleansing without intranasal mupirocin application was used. This dosing schedule, mode of administration and treatment periods correspond to the allowed and recommended standards of Swissmedic and were not modified in this trial. Decolonization occured before hospitalization, as a fully completed course before surgery has been more effective. In some of the previous trials decolonization took place only at the beginning of hospitalization. The decolonization procedure was only completed after surgery had taken place and this possibly affected the results.

For practical reasons the use of a placebo kit within the control group abandoned. Operators, who are also the outcome assessors, will be blinded for either the carrier status or the decolonization procedure. Study participants will be told not to inform surgeons about performed decolonization procedure.

The incidence of PJI at two years in the intervention and control group will be assessed by phone interview.

02

Conditions studied

  • Staphylococcus Aureus
  • Orthopaedic Surgery
  • Surgical Site Infection
  • Prevention
03

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • older than 16 years
  • planned elective orthopedic procedure
  • Decolonization protocol can be performed timely

Exclusion criteria

Exclusion Criteria:

  • No orthopedic prosthetic surgery planned
  • Allergy to mupirocin or chlorhexidine
  • Presence of a nasal foreign body
  • No informed consent
  • undergoing treatment/surgery for a documented infection
  • already participating in the study
04

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
1,318 participants (actual)

Study arms

  • Experimental
    Carrier group - intervention

    BACTROBAN® Nasal ong, 3g, GSK Lifo-Scrub sol 4%®, 500ml, B. Braun

    Drug: Chlorhexidine, Lifo-Scrub sol 4%®, 500ml, B. Braun · Drug: BACTROBAN® Nasal ong

  • No intervention
    Carrier group - control
  • Experimental
    Non - carrier group - intervention

    Lifo-Scrub sol 4%®, 500ml, B. Braun

    Drug: Chlorhexidine, Lifo-Scrub sol 4%®, 500ml, B. Braun

  • No intervention
    Non - carrier group - control

Interventions

  • DrugChlorhexidine, Lifo-Scrub sol 4%®, 500ml, B. Braun

    5 - day decolonization procedure prior elective surgery. In carriers with Chlorhexidine daily showers and Mupirocin twice a day nasal ointment. In non-carriers Chlorhexidine showers will be used.

  • DrugBACTROBAN® Nasal ong

    Mupirocin, BACTROBAN® Nasal ong, 3g, GSK

05

What researchers measure

Primary outcomes

  1. Surgical site infections

    according CDC-Criteria

    Time frame: 2 years

Secondary outcomes

  1. Overall mortality

    Time frame: 2 years

  2. Death related to infection

    Time frame: 2 years

  3. Documented bacteria

    of PJI

    Time frame: 2 years

  4. Time to PJI and death

    counting from operation date

    Time frame: 2 years

06

Study locations

1 site
  • Sonnenhofspital, Lindenhofgruppe
    Bern, 3006, Switzerland
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03962907
Lead sponsor
Lindenhofgruppe AG
Responsible party
Sponsor
First posted
May 24, 2019
Start date
Jan 1, 2019
Primary completion
Mar 30, 2020
Completion
Jun 30, 2020
Last update
Jul 17, 2020

Study contacts

Jan Brügger, MD
principal investigator · Lindenhofgruppe

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion